semaglutide drug Hims & Hers stock falls 25% as FDA curtails compounded GLP-1s Diabetes advocacy group discourages use

Di Zazzo E, Galasso G, Giovannelli P, Di Donato M, Bilancio A, Perillo B, Sinisi AA, Migliaccio A, Castoria G

This is the first of seven peptides the committee is reviewing and there are additional discussions and votes expected Thursday and Friday

The key question will be long-term durability, safety, tolerability, and how these therapies perform in broader real-world populations beyond controlled trials

Food and Drug Administration has cleared Embryo Predict, an artificial-intelligence system designed to provide embryologists with additional information when assessing blastocysts for IVF transfer or freezing

Food and Drug Administration (FDA) has approved semaglutide, a glucagon-like peptide receptor agonist (GLP-1RA), to treat type 2 diabetes mellitus (T2DM) and obesity

Key Takeaways Glutathione IV therapy frequency is highly individualized, not a fixed schedule